# Efficacy of Montelukast on STEMl Patients

Study · id `cardio:ct-nct07320625` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT07320625](<https://clinicaltrials.gov/study/NCT07320625>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT07320625

Browse, organ or system: Heart  
Browse, condition area: Coronary and vascular disease; Acute care and long-term living  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 512 participants.

## Technical summary

Registry record NCT07320625. Randomized; triple masking; primary purpose treatment. Start 2026-02-01 (anticipated); primary completion 2027-02-01 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; triple masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 512 participants (planned count; ClinicalTrials.gov record NCT07320625, source copy `cardio:ctgov-nct07320625-2026-01-13`, retrieved 2026-10-26)
- Planned start: 2026-02-01 (anticipated) (ClinicalTrials.gov record NCT07320625, source copy `cardio:ctgov-nct07320625-2026-01-13`, retrieved 2026-10-26)
- Primary completion: 2027-02-01 (anticipated) (ClinicalTrials.gov record NCT07320625, source copy `cardio:ctgov-nct07320625-2026-01-13`, retrieved 2026-10-26)
- Completion: 2027-05-01 (anticipated) (ClinicalTrials.gov record NCT07320625, source copy `cardio:ctgov-nct07320625-2026-01-13`, retrieved 2026-10-26)
- Countries: China (ClinicalTrials.gov record NCT07320625, source copy `cardio:ctgov-nct07320625-2026-01-13`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct07320625-2026-01-13`, retrieved 2026-10-26)

## The registry's words

- Brief title: Efficacy of Montelukast on STEMl Patients
- Condition: Myocardial Infarction (MI)
- Intervention (Drug): Montelukast
- Intervention (Drug): Placebo
- Lead sponsor: Shanghai Zhongshan Hospital
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Heart attack (myocardial infarction) (`cardio:myocardial-infarction`)
- Registry lists this organization as the lead sponsor: Shanghai Zhongshan Hospital (`cardio:org-shanghai-zhongshan-hospital`)

## Provenance

Content hash: 151ba0bc67d573c196643430451b565e6cc1d4314abf4203555cf1eaaaf5031c
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
